MAX BioPharma has exclusively licensed the small molecule oxysterols from University of California, Los Angeles and Johns Hopkins University in the US.
The pharmaceutical company has also received a Small Business Innovation Research (SBIR) grant from the National Institute of Health for the development of a new drugs based on the oxysterol technology.
Oxysterol technology is claimed to stimulate bone formation locally and systemically in cases including spinal fusion, non-union fractures, and osteoporosis.
Impressive results were displayed by the MAX BioPharma's first lead candidate molecule for stimulating bone formation to treat bone fractures, induce bone fusion in spine surgeries, and regenerate maxillofacial bone defects in a number of preclinical animal models.
The company's success in small molecule lipids contributed to the discovery of novel osteogenic oxysterol compounds that target multipotent mesenchymal cells, including mesenchymal stem cells, to stimulate formation bone forming osteoblasts as well as bone in vitro and in vivo.
